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Case ReportCurative Lung Metastasectomy Without
Concomitant Androgen Deprivation Therapy in
Oligometastatic Castration-resistant Prostate
Cancer: A Case Report and Review of the
Literature
Alessandra Mosca,1 Guglielmo Mantica,2 Marco Giavarra,1 Valentina Perrone,1
Lucrezia De Marchi,1 Alessandra Gennari,1 Carlo Toncini,3 Carlo Terrone1Clinical Practice Points
 The very few reports currently available in the literature
show that an active approach, with curative intent, to
lung metastasis from prostate cancer can be benefi-
cial in terms of biochemical response and disease-free
survival.
 Stereotactic body radiotherapy, associated with
androgen deprivation therapy (ADT), represents the
most experienced treatment option in such patients,
whereas ADT alone is still the gold standard of care.
 We present a case of oligometastatic castration-
resistant prostate cancer in a patient who was
successfully managed by surgical pulmonary meta-
stasectomy followed by ADT interruption.Clinical Genitourinary Cancer, Vol. -, No. -, --- ª 2019 Elsevier Inc. All rights reserved.
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Prostate cancer (PC) metastases commonly involve bones and
lymph nodes (90%), whereas the presence of metastases in other
organs, such as lungs and liver, often correlates with a worse
prognosis and a high burden of disease, amounting to the clinical
setting of polymetastatic PC.1,2
On the other hand, the most common definition of oligometa-
static tumor is the presence of 1 to 5 metastases in less than 2 or-
gans.3,4 In patients with oligometastatic disease by breast, kidney,
lung, or colorectal neoplasms, ablative surgery or radiation therapy
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https://doi.org/10.1016/j.clgc.2019.11.018systemic treatments.4 Conversely, in patients with oligometastatic
PC, ablative treatments are currently not indicated, except for
clinical trials.5-7 In these patients, androgen deprivation therapy
(ADT), achieved with surgical bilateral orchiectomy or luteinising
hormone-releasing hormone (LHRH) agonist/antagonist, is still the
standard treatment, according to international guidelines.7,8
However, related adverse events, such as hot flashes, vasomotor
instability, osteoporosis, fatigue, cardiovascular morbidity, psycho-
logical and cognitive disorders, and metabolic syndrome, may
compromise quality of life, particularly if ADT is administered for
several years.
Here, we describe a clinical case of a patient with PC, who un-
derwent prostatectomy and subsequent adjuvant radiotherapy and
ADT, who later progressed to an oligometastatic castration-resistant
disease, characterized by 2 lung metastases, which were radically
resected through surgery, followed by ADT (LHRH agonist)
withdrawal.
Case Presentation
In March 2005, a 63-year-old man with severe lower urinary
tract symptoms and without comorbidities presented with a
prostate-specific antigen (PSA) of 9.1 ng/mL and a prostatic biopsyClinical Genitourinary Cancer Month 2019 - 1
Figure 1 Computed Tomography Scan Showing 2 Left Lung Metastasis (Blue and Red Arrows)
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Lung Metastasectomy for Recurrent Prostate Cancer for throughoutnegative for PC, and therefore underwent prostatic adenomectomy.
Histologic examination revealed a benign prostatic hyperplasia
associated with a prostatic adenocarcinoma in more than 5% of
tissue resected, with diffuse and intense nuclear positivity for
androgen receptors, Gleason Score 8 (5 þ 3).
He started bicalutamide (150 mg daily) from March to October
2005, and he completed external beam radiotherapy (74 Gy) on the
prostate bed in September 2005. Post-radiotherapy PSA decreased
to a nadir of 0.03 ng/mL in 2007, but it rose to 0.35 ng/mL in
2012, 84 months after radiotherapy.
In 2013, owing to cough, he underwent thorax radiography, which
showed 2 pulmonary micronodules requiring active surveillance. In
the following months, PSA increased to 1.32 ng/mL. A computedFigure 2 A, Diffuse and Intense Nuclear Positivity for Androgen Rec
Receptor Immunostaining); B, Complete Negativity for Cro
Cromogranin-A Immunostaining); C, Diffuse and Intense N
(2003, Androgen Receptor Immunostaining); D, Isolated a
Lung Metastasis (2003, Cromogranin-A Immunostaining)
nical Genitourinary Cancer Month 2019tomography scan performed at the beginning of 2014 pointed out 2
pulmonary lesions (diameters of 15 and 16 mm, respectively),
confirmed by a fluorodeoxyglucose-positron emission tomography
and corresponding to the micronodules previously highlighted by the
radiography (Figure 1). In April 2014, the patient underwent a
transthoracic biopsy, which demonstrated metastases from prostatic
adenocarcinoma (PSAþ, CK7þ/, TTF1, CDX 2) and was
started on ADT with LHRH agonist. After an initial response, with a
PSA lowered to< 0.09mg/mL, the PSA further increased to 0.25 ng/
mL, and a computed tomography scan revealed a volumetric pro-
gression of pulmonary metastasis 2 years later.
From January to November 2016, the patient started total
androgen blockade, adding bicalutamide 50 mg daily to LHRHeptor in the Primary Prostatic Adenocarcinoma (1003, Androgen
mogranin-A in the Primary Prostatic Adenocarcinoma. (1003,
uclear Positivity for Androgen Receptor in the Lung Metastasis.
nd Rare Cells Positive for Cromogranin-A in a Small Area of the
Table 1 Literature Review of Pulmonary Metastasis From PC Managed With Surgical Ablation





Smith11 T2N0 4 þ 5 RP Single, 2 cm No Surgical resection PSA undetectable
Wallis12 T3aN0 4 þ 5 RP þ RT Single, 1 cm No Surgical resection PSA decreased to
0.3 ng/mL at 1 year
Chao13 T2aN0 4 þ 5 RP Single, 1.2 cm No Wedge resection Disease-free at 12
years
Pruthi14 T2bN0 3 þ 3 RP þ RT Single, 2 cm LHRH agonist Surgical resection PSA undetectable
at 3 years
Khandani15 NA NA RT Single, NA No Surgical resection PSA decreased to
0.2 ng/mL
Hofland16 T2cN0 4 þ 5 RP þ RT Single, NA Bilateral orchiectomy Surgical resection Further metastases
developed/lost at
follow-up
Boyer17 T2NX 3 þ 3 RP Single, 2.8 cm Leuprolide Surgical resection PSA decreased at
0.07 ng/mL
Bromberg18 NA 3 þ 3 RP Three, NA Bilateral orchiectomy Wedge resection Resolution of
nodules within
1 year
Maeda19 T2bN0 NA RP Two, NA No Surgical resection NA
Cusan20 NA NA RT Bilateral, NA LHRH agonist and
flutamide
Surgical resection PSA decreased to
0.5 ng/mL











Dead from mPC at
30 months
Rush23 T4N0 4 þ 4 RP Single, 4.7 cm No Surgical resection PSA undetectable
at 24 months
Pepe24 T3aN0 4 þ 3 RP Single, 2 cm No Surgical resection Free from
recurrences at 6
months
Goto25 NA 4 þ 5 RP Single, NA Maximum androgen
blockade
Wedge resection Free from
recurrences at 10
months
Mortier26 T3aN0 3 þ 3 RP þ RT þ
Androgen
deprivation therapy
Single, 2 cm ADT (interrupted at 1
year)
Surgical resection PSA undetectable
at 1 year
Boschian27 T3aN0 4 þ 3 RP þ RT Single, 1 cm No Surgical resection PSA undetectable
at 36 months
Gago28 T3aNx NA RP þ RT Single, NA LHRH agonist Surgical resection No recurrences at 5
months
Reinstatler29 T1Nx 4 þ 4 TURP Multiple, max 2-3 mm Leuprolide þ docetaxel Surgical resection NA
Ciriaco30 T3bN0 4 þ 4 RP Three, NA ADT Wedge resection Clinical recurrence
at 6 months
T2bN0 5 þ 2 RP þ RT þ
Chemotherapy
Three, NA No Wedge resection Biochemical
response at 85
months
T2bN0 5 þ 3 RP þ RT Single, NA No Wedge resection Biochemical
response at 11
months
T3aN0 4 þ 4 RP þ RT Single, NA No Wedge resection Biochemical
response at 47
months
T3aN0 4 þ 4 RP þ RT Single, NA No Wedge resection Biochemical
response at 23
months
T2cN0 4 þ 3 RP þ RT Single, NA No Wedge resection Biochemical
response at 17
months
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Table 1 Continued





T2bN0 3 þ 4 RP Two, NA No Wedge resection Biochemical
response at 77
months
T3aN0 4 þ 4 RP þ RT Six, NA No Wedge resection Biochemical
response at 26
months





T1bN0 5 þ 3 Adenomectomy
þ RT





PubMed and Google Scholar research, performed September 30, 2019: (“lung” [MeSH Terms] OR “lung” [All Fields] OR “pulmonary” [All Fields]) AND (“neoplasm metastasis” [MeSH Terms] OR
(“neoplasm” [All Fields] AND “metastasis” [All Fields]) OR “neoplasm metastasis” [All Fields] OR “metastasis” [All Fields]) AND (“prostate” [MeSH Terms] OR “prostate” [All Fields]) AND (“neoplasms”
[MeSH Terms] OR “neoplasms” [All Fields] OR “cancer” [All Fields]).
Abbreviations: ADT ¼ androgen deprivation therapy; GnRH ¼ gonadotropin-releasing hormone; LHRH ¼ luteinizing hormone-releasing hormone; mPC ¼ metastatic prostate cancer; NA ¼ not
assessed; PC ¼ prostate cancer; PSA ¼ prostate-specific antigen; RP ¼ radical prostatectomy; RT ¼ radiotherapy; TURP ¼ transurethral resection of the prostate.
Lung Metastasectomy for Recurrent Prostate Cancer for throughout
4 - Cliagonist. However, not even that addition was able to stop PSA
growth, which continued to progress up to 0.78 ng/mL, with a
castration level of serum testosterone (below 0.2 ng/dL).
In October 2016, a multidisciplinary discussion among the
oncologist, urologist, and thorax surgeon led them to share the
option of a lung lower lobectomy. As the patient agreed, he un-
derwent a lower lobectomy in November 2016. Immune histo-
chemical analysis confirmed metastases from prostatic
adenocarcinoma, with diffuse and intense nuclear positivity for
androgen receptors, PSA absence, and isolated cells that were
chromogranin-A positive in a small area of lung metastasis,
compatible with a neuroendocrine differentiation (Figure 2). After
lobectomy, PSA became undectectable, and ADT was stopped.
In July 2019, 32 months after the lobectomy, his PSA was
stable at 0.07 ng/mL, his Eastern Cooperative Oncology Group
performance status was 0, and he is continuing surveillance in
absence of ADT.
Discussion
The oligometastatic state is an intermediate stage of cancer spread
between localized disease and widespread metastases.9 This condi-
tion represents a therapeutic “gray zone” for many different tumors
as well as PC. To date, according to the major international
guidelines,7,8 ADT is the gold standard in the management of such
patients, whereas the impact of local tumor ablative therapy in
oligometastasized PC is still under debate. However, over the last
few years, metastasis-directed therapy has also been gaining
importance for patients with PC, with stereotactic body radio-
therapy representing the most experienced treatment option.10
Literature data concerning lung metastasectomy in patients with
oligometastatic PC is limited, with less than 20 single cases and a
unique case series of 9 patients from a single institution published
(Table 1).
The typical patient who develops such pulmonary metastases, as
can be guessed, is a patient with an elevated Gleason score, previ-
ously subjected to radical prostatectomy sometimes followed by
salvage radiotherapy. In the literature, 18 (66.7%) of 27 patients
presented a single pulmonary metastasis, whereas in other cases, thenical Genitourinary Cancer Month 2019nodes were multiple. In 12 (44.4%) of 27 patients a surgical
resection of metastases was associated with an ADT.
Taking into account the huge limits of the heterogeneity of the PC,
the patients, the type and number of pulmonary metastases, the
adjuvant ADT, and the different follow-up, the previous reports show
that 88%of the patients presented a good response to surgical therapy.
Inmost of the reports, this success was evaluatedwith a biochemical
response or with no further metastasis on subsequent imaging.
All 3 patients who did not benefit from surgery were patients who
underwent ADT following surgery. However, this could be influ-
enced by the limited number of the sample as well as publication
bias.
The data on patients’ symptoms or quality of life was not pre-
sented in most reports.
We believe that our case may be emblematic. This is a patient
with PC who has undergone surgery and radiotherapy for PC. He
became metastatic about 8 years after RT and was treated with
LHRH agonist and anti-androgens until the development of
castration resistance. He underwent surgical resection of lung
metastasis, and the ADT was stopped. The histologic examination
showed cells with neuroendocrine immunohistochemical pheno-
type. Thirty-two months after the lobectomy, his PSA was stable at
0.07 ng/mL, his Eastern Cooperative Oncology Group performance
status was 0, and he is continuing active surveillance in the absence
of ADT.
Nowadays, the indication and role of surgical resection of
metastasis in patients with PC is not as defined as in other oncologic
diseases, where metastasis resection in patients with oligometastatic
disease is recommended in national and international guidelines.4
Although with significant limitations, the reports currently
available in the literature show that a surgical approach to lung le-
sions can be beneficial in terms of biochemical response and disease-
free survival.
Furthermore, in patients eligible for this surgery, resection of the
metastases could be useful for patients who are not responsive to
ADT, while also avoiding side effects.
Indication for a surgical resection should be limited to selected
cases after multidisciplinary team discussion.
Alessandra Mosca et alAlthough prospective studies on larger series are needed, the
surgical resection of PC lung metastasis seems to be feasible,
effective, and safe in appropriate patients.
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